Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16182412 | 0.90 | TSHR (0.56) | CES2TSHRRECQLFAAHALDH1A1 | |
| SCHEMBL253658 | 0.88 | CES2 (0.43) | CES2TSHRRECQLFAAHALDH1A1 | |
| SCHEMBL13154532 | 0.87 | CES2 (0.42) | CES2TSHRRECQLFAAHALDH1A1 | |
| SCHEMBL16350546 | 0.86 | CES2 (0.50) | CES2TSHRRECQLFAAHALDH1A1 | |
| SCHEMBL12666244 | 0.86 | CES2 (0.42) | CES2TSHRRECQLFAAHALDH1A1 | |
| SCHEMBL27409799 | 0.85 | TSHR (0.54) | TSHRRECQLFAAHALDH1A1EPHX2 | |
| SCHEMBL15075515 | 0.84 | FAAH (0.56) | CES2TSHRRECQLFAAH | |
| SCHEMBL14793113 | 0.84 | TSHR (0.44) | CES2TSHRRECQLFAAHALDH1A1 | |
| SCHEMBL13034763 | 0.84 | TSHR (0.43) | CES2TSHRRECQLFAAHALDH1A1 | |
| SCHEMBL12899416 | 0.84 | TSHR (0.52) | TSHRRECQLFAAHALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150633-B2 | Insulin analogues with an acyl and alkylene glycol moiety | NOVO NORDISK A/S (DK) | 2015-10-06 | — | — | US | disclosed |
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | NOVO NORDISK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | IAPP, INSR, IGF1R | CES2 2584/4885TSHR 372/4885RECQL 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.